BTG International Limited
7 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 8 name spellings.
6
Ending by 2030
Nov 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 13, 2027The maintenance fee for Reconstitutable reverse thermal gelling polymers (US 9,155,722) comes due Apr 13, 2027. Unpaid by Oct 13, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,700,766 | Methanesulfonate salts of abiraterone-3-esters and recovery of salts of abirater one-3-esters from solution in methyl tert-butyl ether In force · USPTO record | In force | USPTO record | |
| US 7,776,838 | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides In force · USPTO record | In force | USPTO record | |
| US 8,236,946 | Process for the preparation of 17-0-vinyl-triflates as intermediates In force · USPTO record | In force | USPTO record | |
| US 9,155,722 | Reconstitutable reverse thermal gelling polymers In force · USPTO record | In force | USPTO record | |
| US 8,466,111 | Cyclopenta{G}quinazoline derivatives for the treatment of rheumatoid arthritis or acute myeloid leukaemia In force · USPTO record | In force | USPTO record | |
| US RE43,898 | Altered antibodies and their preparation In force · USPTO record | In force | USPTO record | |
| US 8,809,526 | Synthesis of cyclopentaquinazolines In force · USPTO record | In force | USPTO record | |
| US 8,753,621 | BAB triblock polymers having improved release characteristics In force · USPTO record | In force | USPTO record | |
| US 9,458,188 | Efficient peptide couplings and their use in the synthesis and isolation of a cyclopenta (G) quinazoline trisodium salt In force · USPTO record | In force | USPTO record | |
| US 11,026,948 | Platinum-Resistant Cancer Treatment In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 14: 7 patents in force now held by others · 142 lapsed for an unpaid fee · 379 ended at full term · 4 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 5 abandoned · 114 no status recorded